GLPG Stock Analysis: Buy, Sell, or Hold?
GLPG - Galapagos NV
$29.50
-0.27 (-0.89%)
▼
5d:
-1.58%
30d:
-12.45%
90d:
-9.8%
HOLD
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Apr 22, 2026
19d
Get Alerted When GLPG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GLPG shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GLPG shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: GLPG is currently trading at $29.50, which is considered oversold relative to its 30-day fair value range of $30.45 to $33.76. From a valuation perspective, the stock is trading at a discount (Forward PE: -42.7) compared to its historical average (163.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GLPG is showing sideways momentum. The price is currently testing key support at $28.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GLPG has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $33.01 (+10.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GLPG is showing sideways momentum. The price is currently testing key support at $28.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GLPG has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $33.01 (+10.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$30.45 -
$33.76
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
59.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($33.01)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Fair Price Analysis
30-Day Fair Range
$30.45 -
$33.76
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$28.70
Resistance Level
$32.78
Current Trend
Sideways
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-42.67
Wall Street Target
$33.01
(+10.9%)
Revenue Growth (YoY)
1093.2%
Earnings Growth (YoY)
3036.0%
Profit Margin
28.8%
PE vs Historical
-42.7 vs 163.5
CHEAP
Share & Embed Analysis
Last updated: April 02, 2026 11:05 AM ET
Data refreshes hourly during market hours. Next update: 12:05 PM
Data refreshes hourly during market hours. Next update: 12:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLPG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 55 HOLD |
